Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Licenses Nasal Swab Collection Tech to Rhinostics

NEW YORK — Harvard University said on Tuesday that it has licensed a nasal swab collection technology developed at its Wyss Institute for Biologically Inspired Engineering to startup Rhinostics.

Unlike traditional nasal swabs, which are manufactured in two parts that require assembly, the Wyss swabs are fully injection-molded from a single material and can be manufactured in a less expensive, one-step process, according to Harvard. In clinical testing, the swab design has been shown to effectively collect SARS-CoV-2 RNA from nasopharyngeal samples and is compatible with automated instrumentation.

Cambridge, Massachusetts-based Rhinostics plans to use the technology to develop and commercialize automated and multiplexed products for processing nasal samples for SARS-CoV-2 and other respiratory infection testing. Harvard said that the license gives Rhinostics exclusive rights to the nasal swab technology for non-SARS-CoV-2 related applications.

Financial and other terms of the deal were not disclosed.

Rhinostics, which was cofounded by Wyss researchers Richard Novak and Michael Springer, named Cheri Walker as its president and CEO in late 2020.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more